PREMYOM
Myopia epidemic slowdown and disease management by medical optics
PREMYOM is a multidisciplinary consortium of well-known partners from industry, healthcare and research, coordinated by EssilorLuxottica, bringing an unprecedented blend of technical, clinical, and digital expertise: Hôpital Fondation Adolphe de Rothschild, Institut Français de Myopie, Inria, InSimo, Institut Mines-Télécom, and Institut de la Vision.
Features
Project duration
5 years
Start :
End :
Project scale
National project
Allocated budget
Description
La myopie constitue une menace croissante pour la santé publique. D'ici à 2050, environ 4,7 milliards de personnes, soit plus de 50 % de la population mondiale, devraient souffrir de myopie, contre 2,8 milliards aujourd'hui. La myopie affecte la qualité de la vision, augmente à l'âge adulte le risque de maladies oculaires telles que le glaucome ou de décollement de la rétine et réduit la qualité de vie.
Myopia is a growing public health threat. By 2050, approx. 4.7 billion people, i.e. more than 50% of the world’s population is expected to suffer from myopia, up from 2.8 billion today. It affects vision quality, increases the risk of eye diseases such as glaucoma or retina delamination, and reduces quality of life. Up to one billion people will be high myopes (superior to -5 Diopters) by 2050, risking blindness.
Current myopia control solutions are not personalized and do not address the individual underlying causes of myopia progression.
PREMYOM aims to bring myopia management in a new personalization era by investigating both the clinical and biological factors of myopia progression and developing innovative ophthalmic solutions that are tailored to each individual's needs and preferences.
The project has been selected for co-funding by the French Prime Minister's Secrétariat Général Pour l’Investissement (SGPI) and its operating agency Bpifrance as part of the France 2030 plan and i-Demo-2 State funding, highlighting the critical importance of addressing children's visual health as a major public health issue and tackling European myopia epidemic
